Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
Completed
This is a modified single-blind, randomized, parallel-group, comparative, multicenter study to test Menactra vaccine in toddlers. Primary Objectives: * To evaluate the antibody responses induced by Measles, Mumps, Rubella, and Varicella (MMRV) vaccine when administered alone or concomitantly with Menactra vaccine. * To evaluate the antibody responses induced by Pneumococcal Conjugated Vaccine (PCV) when administered alone or concomitantly with Menactra vaccine. Observational Objectives: Safe... Read More
Gender:
ALL
Ages:
Between 9 months and 12 months
Trial Updated:
04/12/2016
Locations: Not set, Brooklyn, New York +8 locations
Conditions: Meningococcal Meningitis, Measles, Mumps, Rubella, Varicella
Immunization With a Pentavalent Vaccine Composed of KLH-conjugates of GD2L, GD3L, Globo H, Fucosyl GM1, and N-Propionylated Polysialic Acid
Completed
Even when small cell lung cancer responds well to treatment with chemotherapy, it has a tendency to grow back and to spread. The investigators are interested in testing new therapies aimed at decreasing this risk. This study tests a vaccine, which is a substance injected under the skin which can cause an immune response. The hope is that the body will make antibodies to the vaccine which will also react against the cancer. The vaccine is specific for small cell lung cancer. It combines several c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/04/2016
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Lung Cancer
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
Terminated
RATIONALE: Vaccines made from a person's melanoma cells may make the body build an immune response to kill tumor cells. Interferon alfa may interfere with the growth of the cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of melanoma vaccine with that of interferon alfa-2b in treating patients who have stage III melanoma that has spread to regional lymph nodes following surgery.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
12/02/2015
Locations: Herbert Irving Comprehensive Cancer Center, New York, New York
Conditions: Melanoma (Skin)
Vaccine Therapy in Treating Patients With Recurrent B-Cell Lymphoma
Completed
RATIONALE: Vaccines made from mouse DNA may help the body build an effective immune response to kill cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of mouse DNA vaccine in treating patients with recurrent B-cell lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/16/2015
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Lymphoma
Prospective Trial of Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older
Completed
Infections due to influenza and pneumococcus can be very serious and cause death. Anyone can get these infections. However, some people are at greater risk from the disease, including people 65 and older, the very young, and people with special health problems such as people with certain types of cancer, heart, lung, or kidney disease, or diabetes. Influenza can cause a very serious lung infection (pneumonia) and increase the risk of stroke and heart attacks. Pneumococcal disease can lead to ser... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
10/19/2015
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer
Completed
Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. Biological therapies, such as GM-CSF, may stimulate the immune system in different ways and stop tumor cells from growing. Androgens can cause the growth of prostate cancer cells. Drugs, such as bicalutamide and goserelin, may stop the adrenal glands from making androgens in patients whose tumor cells continue to grow. Giving vaccine therapy together with GM-CSF and, when needed, an... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/03/2015
Locations: New York University Langone Medical Center, New York, New York
Conditions: Recurrent Prostate Carcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children
Completed
Human parainfluenza virus type 3 (HPIV3) is a major cause of pneumonia and other respiratory diseases in infants and children. This study will evaluate the safety and immune response of an HPIV3 vaccine in infants and young children.
Gender:
ALL
Ages:
Between 6 months and 36 months
Trial Updated:
12/02/2014
Locations: Columbia IMPAACT CRS, New York, New York
Conditions: Parainfluenza Virus 3, Human
Controlling Acute or Early HIV Infection With Antiretroviral Drugs, Without a Candidate Vaccine.As Reported Previously, the Candidate Vaccie Was Not Provided by the Maufacturer as Promised
Completed
The purpose of this study is to determine the role of HIV-specific CD4 T cell responses and immune responses dependent upon these CD4 responses that develop when antiretroviral drugs are started during acute or recent HIV infection, whether these CD4 responses can be enhanced with a therapeutic HIV vaccine (HIV-1 immunogen), and what pattern of HIV-specific immune responses is associated with control of HIV upon discontinuation of antiretroviral drugs during an analytical therapeutic interruptio... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
11/19/2013
Locations: New York University School of Medicine, New York, New York
Conditions: HIV Infections
Study of Quadrivalent Influenza Vaccine Among Adults
Completed
The aim of the study is to evaluate a prototype quadrivalent influenza vaccine (QIV), the licensed 2010-2011 trivalent influenza vaccine (TIV) containing the primary B strain, and the investigational TIV containing the alternate B strain in adult subjects. Primary Objective: * To demonstrate non-inferiority of antibody responses to QIV compared with licensed 2010-2011 TIV (containing the primary B strain) and investigational TIV (containing the alternate B strain) as assessed by geometric mean... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/13/2013
Locations: Not set, New York, New York +1 locations
Conditions: Influenza
Vaccine Therapy Plus Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer That Has Been Completely Removed in Surgery
Completed
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining these two treatments may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining vaccine therapy with radiation therapy in treating patients who have stage II or stage IIIA non-small cell lung cancer that has been completely removed in surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/09/2013
Locations: Cancer Center of Albany Medical Center, Albany, New York +12 locations
Conditions: Lung Cancer
Biological Therapy in Treating Patients With Prostate Cancer
Completed
RATIONALE: Interleukin-2 may stimulate a person's white blood cells including natural killer cells to kill prostate cancer cells. Interferon gamma may interfere with the growth of the cancer cells. Combining interferon gamma with interleukin-2 may be a more effective treatment for prostate cancer. PURPOSE: Phase I/II trial to study the effectiveness of biological therapy using interleukin-2 and interferon gamma in treating patients with advanced prostate cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/24/2013
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Prostate Cancer
Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer
Completed
RATIONALE: Vaccines made from a person's cancer cells may make the body build an immune response to kill the tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have ovarian, fallopian tube, or peritoneal cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/17/2013
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer